二甲双胍降低关节镜下肩袖修复术后肩关节僵硬发生率:一项随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验将146例肩袖撕裂患者随机分为二甲双胍组(500毫克,每日两次,术后3个月)和安慰剂组,最终126例完成随访。二甲双胍组术后3个月肩关节僵硬发生率为11%,显著低于对照组的27%(风险比0.40,95%CI 0.18-0.90,P=0.02)。两组1年随访时ASES评分、疼痛和满意度无显著差异,肌腱愈合率相当。
要点
- 术后3个月二甲双胍组肩关节僵硬发生率为11%,对照组为27%(风险比0.40,95%CI 0.18-0.90,P=0.02)。
- 两组1年随访时ASES评分、疼痛和满意度评分无显著差异。
- 二甲双胍组血浆纤维化生物标志物浓度显著低于对照组,两组肌腱愈合率相当(风险比0.97,95%CI 0.86-1.10,P=0.83)。
核心结论
- 二甲双胍治疗降低了关节镜下肩袖修复术后肩关节僵硬的发生率。
- 二甲双胍未对肩袖肌腱愈合产生负面影响。
- 这些发现表明二甲双胍是术后肩关节僵硬的潜在药物预防手段。
研究设计与样本
- 随机对照试验,证据等级1级。
- 共146例连续肩袖撕裂患者随机接受二甲双胍500毫克或安慰剂每日两次,术后使用3个月。
- 最终126例获得完整结局测量,其中二甲双胍组64例,对照组62例。
主要发现
- 术后3个月肩关节僵硬发生率二甲双胍组为11%,对照组为27%(风险比0.40,95%CI 0.18-0.90,P=0.02)。
- 1年随访时两组ASES评分、疼痛和满意度评分无显著差异。
- 二甲双胍组血浆纤维化生物标志物浓度显著低于对照组。
- 末次随访时两组肌腱愈合率相当(风险比0.97,95%CI 0.86-1.10,P=0.83)。
关键数值与推荐
- 主要结局为术后3个月随访时肩关节僵硬的发生率。
- 次要结局包括术后第一年的ASES评分、疼痛和患者满意度,以及术后3个月随访时血浆纤维化生物标志物浓度。
- 安全性通过不良事件评估,肩袖肌腱愈合通过超声评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shoulder stiffness after arthroscopic rotator cuff repair (RCR) is associated with a prolonged rehabilitation process and impaired functional outcomes. Previous studies have demonstrated that metformin can alleviate joint stiffness in animal models. However, its clinical effectiveness and safety require further confirmation in clinical practice. PURPOSE/HYPOTHESIS: The purpose of this study was to investigate whether 3 months of postoperative treatment with metformin, compared with placebo, reduced the incidence of shoulder stiffness in patients after arthroscopic RCR. It was hypothesized that the postoperative administration of metformin would decrease the risk of postoperative shoulder stiffness. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: A total of 146 consecutive patients with rotator cuff tears were randomly assigned to receive a 500-mg dose of metformin or placebo twice daily for 3 months after arthroscopic RCR. The primary outcome was the incidence of shoulder stiffness at 3 months' follow-up. Secondary outcomes included the American Shoulder and Elbow Surgeons (ASES) score, pain, and patient satisfaction during the first postoperative year as well as concentrations of plasma fibrotic biomarkers at 3 months' follow-up. The primary and secondary outcomes were measured at baseline and 3 months, 6 months, and 1 year postoperatively. Safety was assessed by adverse events, and rotator cuff tendon healing was evaluated by ultrasonography. RESULTS: Complete outcome measurements were obtained for 126 patients. There were 64 participants in the metformin group and 62 in the control group. The incidence of shoulder stiffness was significantly lower in the metformin group than in the control group at 3 months postoperatively (11% vs 27%, respectively; risk ratio, 0.40 [95% CI, 0.18-0.90]; P = .02). There was no significant difference regarding ASES, pain, and satisfaction scores between groups at 1-year follow-up. The concentrations of plasma fibrotic biomarkers were significantly lower in the metformin group than in the control group. The tendon healing rates were comparable between the 2 groups at final follow-up (risk ratio, 0.97 [95% CI, 0.86-1.10]; P = .83). CONCLUSION: Metformin treatment reduced the incidence of shoulder stiffness after arthroscopic RCR. Metformin did not negatively influence rotator cuff tendon healing. These findings indicated that metformin is a potential pharmacological prophylaxis for postoperative shoulder stiffness. REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300074329).
引用
- Feng J, Huang K, Wu D, et al. Metformin Reduces the Incidence of Shoulder Stiffness After Arthroscopic Rotator Cuff Repair: A Randomized, Double-Blinded, Placebo-Controlled Trial. Am J Sports Med. 2025. PMID: 41105117. doi:10.1177/03635465251380296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。